127
Participants
Start Date
February 8, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
Galinpepimut-S
Galinpepimut-S admixed with the adjuvant Montanide following specified schedule
Azacitidine
injection
Venetoclax
tablet
Decitabine
injection
Cytarabine
injection
Observation
palliative management
GM-CSF
subcutaneous injection
Montanide
adjuvant
National Taiwan University Hospital, Taipei
National Cheng Kung University Hospital, Tainan City
Kaohsiung Medical University Hospital, Kaohsiung City
Semmelweis Egyetem, Budapest
Pécsi Tudományegyetem, Pécs
Petz Aladár Egyetemi Oktató Kórház, Győr
Hospital de San Pedro de Alcantara, Cáceres
New York Medical College, Valhalla
"General Hospital of Athens Evaggelismos", Athens
University Clinical Center of Serbia, Belgrade
Northwell Health Cancer Institute, Lake Success
"General Hospital of Athens Laiko", Athens
"General Hospital of Athens G. Gennimatas", Athens
"General Hospital of Athens Ηippokration", Athens
"University General Hospital Attikon", Chaïdári
CHU de Caen, Caen
C.H. Regional Reina Sofia, Córdoba
Universitätsklinik Rostock, Rostock
Virginia Cancer Specialists, Gainesville
University General Hospital of Patras, Rio
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Universitario La Paz, Madrid
Bon Secours St. Francis Cancer Center, Greenville
Augusta University, Augusta
Clinica Universidad Navarra, Pamplona
Mayo Clinic Jacksonville Florida, Jacksonville
Hospital Universitario Central de Asturias, Oviedo
O'Neal Comprehensive Cancer Center, Birmingham
Complejo Asistencial Universitario de Salamanca, Salamanca
CHU de Grenoble, Grenoble
Taichung Veterans General Hospital, Taichung
Hospital Universitario Virgen del Rocio, Seville
Hôtel Dieu - Nantes, Nantes
University Hospitals Cleveland Medical Center, Cleveland
University General Hospital of Ioannina, Ioannina
Hospital Universitari i Politecnic La Fe de Valencia, Valencia
CHU Angers, Angers
Changhua Christian Hospital, Chang-hua
"University General Hospital of Thessaloniki Ahepa", Thessaloniki
"General Hospital of Thessaloniki G. Papanikolaou", Chortiatis
Rush University Cancer Center, Chicago
University General Hospital of Alexandroupoli, Alexandroupoli
Centre Hospitalier Lyon Sud, Pierre-Bénite
Tulane Cancer Center - Liberty, New Orleans
Baylor Scott and White Research Institute, Dallas
Hôpital Saint Antoine, Paris
University of Texas - MD Anderson Cancer Center, Houston
CHU Amiens-Picardie - Hopital Sud, Amiens
Colorado Blood Cancer Institute - SCRI - PPDS, Denver
CHU de Poitiers, Poitiers
UCLA Medical Hematology and Oncology, Los Angeles
The Oncology Institute of Hope and Innovation, Whittier
Institut Gustave Roussy, Villejuif
Oregon Health and Science University, Portland
Swedish Cancer Institute, Seattle
All India Institute of Medical Sciences, New Delhi
Fortis Hospital, Ludhiāna
Clinical Centre of Vojvodina, Novi Sad
Yashoda Hospital, Hyderabad
Malabar Cancer Centre, Kannur
State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna
Klinikum Chemnitz gGmbH, Chemnitz
Universitatsklinikum Leipzig, Leipzig
Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz
Uniwersyteckie Centrum Kliniczne Klinika Hematologii i Transplantologii, Gdansk
Szpitale Pomorskie Sp. z o.o., Gdynia
Swietokrzyskie Centrum Onkologii, Kielce
Wojewodzki Szpital Specjalistyczny w Legnicy, Legnica
Zaklad Opieki Zdrowotnej MSW z Warminsko-Mazurskim Centrum Onkologii, Olsztyn
Szpital Wojewodzki w Opolu, Opole
SP ZOZ Szpital Uniwersytecki w Krakowie, Słomniki
Instytut Hematologii i Transfuzjologii, Warsaw
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu, Wroclaw
Lead Sponsor
Collaborators (1)
PPD Development, LP
INDUSTRY
Sellas Life Sciences Group
INDUSTRY